BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37977105)

  • 1. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
    Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
    Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
    BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database.
    Gougis P; Carton M; Tchokothe C; Campone M; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Bachelot T; Hennequin A; Perrin C; Gonçalves A; Uwer L; Eymard JC; Petit T; Mouret-Reynier MA; Chamorey E; Simon G; Saghatchian M; Cailliot C; Le Tourneau C
    Breast; 2020 Feb; 49():17-24. PubMed ID: 31675683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
    Annonay M; Gauquelin L; Geiss R; Ung M; Cristol-Dalstein L; Mouret-Reynier MA; Goncalves A; Abadie-Lacourtoisie S; Francois E; Perrin C; Le Fel J; Lorgis V; Servent V; Uwer L; Jouannaud C; Leheurteur M; Joly F; Campion L; Courtinard C; Villacroux O; Petit T; Soubeyran P; Terret C; Bellera C; Brain E; Delaloge S
    Breast; 2021 Dec; 60():138-146. PubMed ID: 34624756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
    Frank S; Carton M; Dubot C; Campone M; Pistilli B; Dalenc F; Mailliez A; Levy C; D'Hondt V; Debled M; Vermeulin T; Coudert B; Perrin C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Patsouris A; Guesmia T; Bachelot T; Robain M; Cottu P
    Breast; 2020 Aug; 52():50-57. PubMed ID: 32380440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
    Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
    ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
    Le Du F; Carton M; Bachelot T; Saghatchian M; Pistilli B; Brain E; Loirat D; Vanlemmens L; Vermeulin T; Emile G; Gonçalves A; Ung M; Robert M; Jaffre A; Desmoulins I; Jouannaud C; Uwer L; Marc Ferrero J; Mouret-Reynier MA; Jacot W; Chevrot M; Delaloge S; Diéras V
    Oncologist; 2023 Oct; 28(10):e867-e876. PubMed ID: 37589218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study.
    Heudel P; Delaloge S; Parent D; Madranges N; Levy C; Dalenc F; Brain E; Uwer L; D'Hondt V; Augereau P; Mailliez A; Perrin C; Frenel JS; Sablin MP; Mouret-Reynier MA; Vermeulin T; Eymard JC; Petit T; Ferrero JM; Ilie S; Goncalves A; Chenuc G; Robain M; Simon G; Perol D
    Anticancer Res; 2020 Jul; 40(7):3905-3913. PubMed ID: 32620631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
    Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
    Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
    Brufsky A; Liu X; Li B; McRoy L; Layman RM
    Front Oncol; 2022; 12():865292. PubMed ID: 35860587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    Quek RGW; Mardekian J
    Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Prognostic Factor Index Among Women With HR
    Vidal GA; Carter GC; Gilligan AM; Saverno K; Zhu YE; Price GL; DeLuca A; Smyth EN; Rybowski S; Huang YJ; Schwartzberg LS
    Clin Breast Cancer; 2021 Aug; 21(4):317-328.e7. PubMed ID: 33678566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Pasquier D; Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Petit A; Mouret-Reynier MA; Goncalves A; Dalenc F; Deluche E; Fresnel JS; Augereau P; Ferrero JM; Geffrelot J; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Mouttet-Audouard R; Bachelot T; Courtinard C
    Eur J Cancer; 2020 Jan; 125():22-30. PubMed ID: 31835235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
    Hotton J; Lusque A; Leufflen L; Campone M; Levy C; Honart JF; Mailliez A; Debled M; Gutowski M; Leheurteur M; Goncalves A; Jankowski C; Guillermet S; Bachelot T; Ferrero JM; Eymard JC; Petit T; Pouget N; de La Lande B; Frenel JS; Villacroux O; Simon G; Pons-Tostivint E; Marchai F
    Ann Surg; 2023 Jan; 277(1):e153-e161. PubMed ID: 33534229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer.
    Rugo HS; Liu X; Li B; McRoy L; Layman RM; Brufsky A
    Breast; 2023 Jun; 69():375-381. PubMed ID: 37080011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.